BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 33972619)

  • 1. Biomechanical regulation of breast cancer metastasis and progression.
    Spencer A; Sligar AD; Chavarria D; Lee J; Choksi D; Patil NP; Lee H; Veith AP; Riley WJ; Desai S; Abbaspour A; Singeetham R; Baker AB
    Sci Rep; 2021 May; 11(1):9838. PubMed ID: 33972619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PI3Kγδ inhibitor plus radiation enhances the antitumour immune effect of PD-1 blockade in syngenic murine breast cancer and humanised patient-derived xenograft model.
    Han MG; Jang BS; Kang MH; Na D; Kim IA
    Eur J Cancer; 2021 Nov; 157():450-463. PubMed ID: 34601286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.
    Vora SR; Juric D; Kim N; Mino-Kenudson M; Huynh T; Costa C; Lockerman EL; Pollack SF; Liu M; Li X; Lehar J; Wiesmann M; Wartmann M; Chen Y; Cao ZA; Pinzon-Ortiz M; Kim S; Schlegel R; Huang A; Engelman JA
    Cancer Cell; 2014 Jul; 26(1):136-49. PubMed ID: 25002028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of genomic and non-genomic signaling of estrogen receptor in PDX models of breast cancer treated with a combination of the PI3K inhibitor alpelisib (BYL719) and fulvestrant.
    Jacquemetton J; Kassem L; Poulard C; Dahmani A; De Plater L; Montaudon E; Sourd L; Morisset L; El Botty R; Chateau-Joubert S; Vacher S; Bièche I; Treilleux I; Trédan O; Marangoni E; Le Romancer M
    Breast Cancer Res; 2021 May; 23(1):57. PubMed ID: 34020697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcriptional suppression of AMPKα1 promotes breast cancer metastasis upon oncogene activation.
    Yi Y; Chen D; Ao J; Zhang W; Yi J; Ren X; Fei J; Li F; Niu M; Chen H; Luo Y; Luo Z; Xiao ZJ
    Proc Natl Acad Sci U S A; 2020 Apr; 117(14):8013-8021. PubMed ID: 32193335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NDAT Targets PI3K-Mediated PD-L1 Upregulation to Reduce Proliferation in Gefitinib-Resistant Colorectal Cancer.
    Huang TY; Chang TC; Chin YT; Pan YS; Chang WJ; Liu FC; Hastuti ED; Chiu SJ; Wang SH; Changou CA; Li ZL; Chen YR; Chu HR; Shih YJ; Cheng RH; Wu A; Lin HY; Wang K; Whang-Peng J; Mousa SA; Davis PJ
    Cells; 2020 Aug; 9(8):. PubMed ID: 32756527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GSK-3 inhibition overcomes chemoresistance in human breast cancer.
    Ugolkov A; Gaisina I; Zhang JS; Billadeau DD; White K; Kozikowski A; Jain S; Cristofanilli M; Giles F; O'Halloran T; Cryns VL; Mazar AP
    Cancer Lett; 2016 Oct; 380(2):384-392. PubMed ID: 27424289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dll1
    Kumar S; Nandi A; Singh S; Regulapati R; Li N; Tobias JW; Siebel CW; Blanco MA; Klein-Szanto AJ; Lengner C; Welm AL; Kang Y; Chakrabarti R
    Nat Commun; 2021 Jan; 12(1):432. PubMed ID: 33462238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.
    Sato H; Yamamoto H; Sakaguchi M; Shien K; Tomida S; Shien T; Ikeda H; Hatono M; Torigoe H; Namba K; Yoshioka T; Kurihara E; Ogoshi Y; Takahashi Y; Soh J; Toyooka S
    Cancer Sci; 2018 Oct; 109(10):3183-3196. PubMed ID: 30098066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin II enhances the proliferation of Natural Killer/T-cell lymphoma cells via activating PI3K/Akt signaling pathway.
    Zhang GH; Miao FA; Xu JG; Zhang Y
    Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 32969473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NVP-BEZ235 or JAKi Treatment leads to decreased survival of examined GBM and BBC cells.
    Vazquez N; Lopez A; Cuello V; Persans M; Schuenzel E; Innis-Whitehouse W; Keniry M
    Cancer Treat Res Commun; 2021; 27():100340. PubMed ID: 33636591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors.
    Sheppard KE; Cullinane C; Hannan KM; Wall M; Chan J; Barber F; Foo J; Cameron D; Neilsen A; Ng P; Ellul J; Kleinschmidt M; Kinross KM; Bowtell DD; Christensen JG; Hicks RJ; Johnstone RW; McArthur GA; Hannan RD; Phillips WA; Pearson RB
    Eur J Cancer; 2013 Dec; 49(18):3936-44. PubMed ID: 24011934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of vitamin D on malignant behavior of non-small cell lung cancer cells.
    Songyang Y; Song T; Shi Z; Li W; Yang S; Li D
    Gene; 2021 Feb; 768():145309. PubMed ID: 33197518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 14, 15-EET induces breast cancer cell EMT and cisplatin resistance by up-regulating integrin αvβ3 and activating FAK/PI3K/AKT signaling.
    Luo J; Yao JF; Deng XF; Zheng XD; Jia M; Wang YQ; Huang Y; Zhu JH
    J Exp Clin Cancer Res; 2018 Feb; 37(1):23. PubMed ID: 29426357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors.
    Chen Y; Guggisberg N; Jorda M; Gonzalez-Angulo A; Hennessy B; Mills GB; Tan CK; Slingerland JM
    Clin Cancer Res; 2009 May; 15(10):3396-405. PubMed ID: 19451593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer stem cells and breast cancer metastasis by downregulating DLL4 and Notch4.
    McClements L; Annett S; Yakkundi A; O'Rourke M; Valentine A; Moustafa N; Alqudah A; Simões BM; Furlong F; Short A; McIntosh SA; McCarthy HO; Clarke RB; Robson T
    BMC Cancer; 2019 Apr; 19(1):351. PubMed ID: 30975104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting PIK3CA Alterations in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Advanced Breast Cancer: New Therapeutic Approaches and Practical Considerations.
    Schwartzberg LS; Vidal GA
    Clin Breast Cancer; 2020 Aug; 20(4):e439-e449. PubMed ID: 32278641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are Wnt/β-Catenin and PI3K/AKT/mTORC1 Distinct Pathways in Colorectal Cancer?
    Prossomariti A; Piazzi G; Alquati C; Ricciardiello L
    Cell Mol Gastroenterol Hepatol; 2020; 10(3):491-506. PubMed ID: 32334125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway.
    Ramaswamy B; Lu Y; Teng KY; Nuovo G; Li X; Shapiro CL; Majumder S
    Cancer Res; 2012 Oct; 72(19):5048-59. PubMed ID: 22875023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of resveratrol on doxorubicin resistance in breast neoplasm cells by modulating PI3K/Akt signaling pathway.
    Chen JM; Bai JY; Yang KX
    IUBMB Life; 2018 Jun; 70(6):491-500. PubMed ID: 29637742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.